Noxopharm Limited (NOXOF)
USD 0.05
(0.0%)
USD 0.05
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 | -2.31 Million AUD | 22.89% |
| 2023 | -3 Million AUD | 78.28% |
| 2022 | -13.85 Million AUD | 47.63% |
| 2021 | -26.44 Million AUD | -1159.3% |
| 2020 | -2.1 Million AUD | -305.73% |
| 2019 | 1.02 Million AUD | 110.94% |
| 2018 | -9.33 Million AUD | -279.77% |
| 2017 | -2.45 Million AUD | -1426.99% |
| 2016 | -160.96 Thousand AUD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q4 | -2.31 Million AUD | 0.0% |
| 2024 Q3 | -2.31 Million AUD | 55.04% |
| 2024 Q2 | -5.15 Million AUD | 0.0% |
| 2024 Q1 | -5.15 Million AUD | -71.49% |
| 2024 FY | -2.31 Million AUD | 22.89% |
| 2023 Q2 | -11.1 Million AUD | 0.11% |
| 2023 Q4 | -3 Million AUD | 0.0% |
| 2023 FY | -3 Million AUD | 78.28% |
| 2023 Q1 | -11.12 Million AUD | 19.7% |
| 2023 Q3 | -3 Million AUD | 72.92% |
| 2022 Q2 | -16.4 Million AUD | 1.66% |
| 2022 Q4 | -13.85 Million AUD | 1.15% |
| 2022 FY | -13.85 Million AUD | 47.63% |
| 2022 Q1 | -16.67 Million AUD | 36.93% |
| 2022 Q3 | -14.01 Million AUD | 14.58% |
| 2021 Q1 | -18.69 Million AUD | -790.08% |
| 2021 FY | -26.44 Million AUD | -1159.3% |
| 2021 Q4 | -26.44 Million AUD | 0.87% |
| 2021 Q3 | -26.67 Million AUD | -44.33% |
| 2021 Q2 | -18.48 Million AUD | 1.11% |
| 2020 Q1 | 5.81 Million AUD | 469.4% |
| 2020 Q3 | -2.34 Million AUD | -140.34% |
| 2020 Q2 | 5.81 Million AUD | 0.0% |
| 2020 FY | -2.1 Million AUD | -305.73% |
| 2020 Q4 | -2.1 Million AUD | 10.44% |
| 2019 Q1 | -6 Million AUD | 35.65% |
| 2019 Q2 | -6 Million AUD | 0.0% |
| 2019 Q3 | 1.02 Million AUD | 116.99% |
| 2019 FY | 1.02 Million AUD | 110.94% |
| 2019 Q4 | 1.02 Million AUD | 0.0% |
| 2018 Q3 | -9.33 Million AUD | -134.0% |
| 2018 FY | -9.33 Million AUD | -279.77% |
| 2018 Q1 | -3.98 Million AUD | -62.29% |
| 2018 Q2 | -3.98 Million AUD | 0.0% |
| 2018 Q4 | -9.33 Million AUD | 0.0% |
| 2017 Q1 | -4.33 Million AUD | -2591.51% |
| 2017 Q4 | -2.45 Million AUD | 0.0% |
| 2017 Q3 | -2.45 Million AUD | 43.27% |
| 2017 FY | -2.45 Million AUD | -1426.99% |
| 2017 Q2 | -4.33 Million AUD | 0.0% |
| 2016 FY | -160.96 Thousand AUD | 0.0% |
| 2016 Q4 | -160.96 Thousand AUD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Qrons Inc. | 351.42 Thousand USD | 760.145% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | 105.341% |
| Capstone Therapeutics Corp. | 20.27 Million USD | 111.442% |
| Adynxx, Inc. | - USD | Infinity% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | 63.202% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | -11267.733% |
| BioStem Technologies, Inc. | 4.47 Million USD | 151.877% |
| Evofem Biosciences, Inc. | 42.79 Million USD | 105.421% |
| Skye Bioscience, Inc. | -5.72 Million USD | 59.452% |
| Rebus Holdings, Inc. | 305 Thousand USD | 860.632% |
| Arch Therapeutics, Inc. | 5.64 Million USD | 141.073% |
| Burzynski Research Institute, Inc. | -1310.00 USD | -176993.664% |
| Neon Bloom, Inc. | 622.36 Thousand USD | 472.76% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | -829.383% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | 11777.289% |
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | 114.718% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | 156.336% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | 677.313% |
| SQZ Biotechnologies Company | -36.23 Million USD | 93.598% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | 203.465% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | 350.212% |
| Mesoblast Limited | 55.85 Million USD | 104.153% |
| Marizyme, Inc. | 18.56 Million USD | 112.494% |
| Genus plc | 190.6 Million USD | 101.217% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | 203.761% |
| Pharming Group N.V. | 109.8 Million USD | 102.113% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | 369.683% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | 291.115% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | 441.166% |
| ContraFect Corporation | -6.02 Million USD | 61.501% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | 1823.072% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | 300.785% |
| IMV Inc. | 7.67 Million USD | 130.245% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | 142.166% |
| MultiCell Technologies, Inc. | 90.04 USD | 2576651.533% |
| ONE Bio Corp. | 9.04 Million USD | 125.663% |
| Accustem Sciences Inc. | -733.97 Thousand USD | -216.076% |
| RVL Pharmaceuticals plc | 12.94 Million USD | 117.92% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | 1.36 Million USD | 269.589% |
| Q BioMed Inc. | 4.06 Million USD | 157.141% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | 107.593% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | 330.216% |
| Biomind Labs Inc. | 711.4 Thousand USD | 426.106% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | 103.832% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | 216.032% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | 118.115% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | 744.944% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | 1759.414% |
| Curative Biotechnology, Inc. | 2.2 Million USD | 205.356% |
| GB Sciences, Inc. | 1.74 Million USD | 232.771% |
| Alpha Cognition Inc. | -183.78 Thousand USD | -1162.284% |
| HST Global, Inc. | 96.79 Thousand USD | 2496.792% |
| CSL Limited | 10.52 Billion USD | 100.022% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | 1224.993% |
| Halberd Corporation | 144.72 Thousand USD | 1703.034% |
| Enzolytics Inc. | 981.65 Thousand USD | 336.328% |
| Agentix Corp. | 37.63 Thousand USD | 6264.936% |
| Resverlogix Corp. | 6.45 Million USD | 135.962% |
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | -244.669% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -2.02 Billion USD | 99.886% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | 95.065% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 132.809% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 185.65% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | 73.756% |
| AVAX Technologies, Inc. | -5.9 Million USD | 60.701% |
| Zenith Capital Corp. | 10.06 Thousand USD | 23151.739% |
| Genscript Biotech Corporation | -1.06 Billion USD | 99.781% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | 1257.463% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | 197.229% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | 1510.213% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | -12564.74% |
| Kadimastem Ltd | -253.1 Thousand USD | -816.598% |
| Helix BioMedix, Inc. | -2.57 Million USD | 9.732% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | 201.25 Thousand USD | 1252.736% |
| LadRx Corporation | -2.03 Million USD | -13.919% |
| Cell Source, Inc. | 9.23 Million USD | 125.129% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 465.247% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 465.247% |
| NovAccess Global Inc. | 2.17 Million USD | 206.494% |
| Affymax, Inc. | -5.59 Million USD | 58.551% |
| Itoco Inc. | 228.3 Thousand USD | 1116.153% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | 1805.967% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | 146.801% |
| Mobile Lads Corp. | 484.23 Thousand USD | 579.094% |
| CytoDyn Inc. | 20.26 Million USD | 111.45% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -647.00 USD | -358466.77% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | -24930.664% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | 130.105% |
| SYBLEU INC | 473.71 Thousand USD | 589.732% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | 152.051% |
| International Stem Cell Corporation | 2.59 Million USD | 189.572% |
| Bioxytran, Inc. | 1.89 Million USD | 222.171% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | 3817.057% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | 206.375% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | 3.43 Million USD | 167.558% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | 127.124% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | 772.6 Thousand USD | 400.273% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | -85.594% |
| Neutra Corp. | 52.18 Thousand USD | 4545.412% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | 6.793% |
| PureTech Health plc | -167.19 Million USD | 98.612% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | -847.265% |
| IXICO plc | -4.44 Million USD | 47.803% |
| IntelGenx Technologies Corp. | 13.21 Million USD | 117.55% |
| Gelesis Holdings, Inc. | 54.85 Million USD | 104.23% |
| CSL Limited | 10.52 Billion USD | 100.022% |
| Cellectis S.A. | -43.81 Million USD | 94.706% |